Australia is paying GPs extra to stop charging patients out of pocket
A $7.9 billion program now pays practices an additional 12.5% on top of the standard Medicare rebate for every bulk-billed visit — split evenly between the clinic and the doctor who sees the patient.
Australia's Bulk Billing Practice Incentive Program, backed by a $7.9 billion government investment, began paying eligible general practices an extra 12.5% on top of the standard Medicare Benefits Schedule rebate for every bulk-billed service, starting 1 November 2025 [s1]. The incentive is split evenly between the practice and the individual provider who saw the patient [s1].
What bulk billing actually means, and why it needed a new incentive
Bulk billing is Australia's system for fully covering a medical visit through Medicare, with no out-of-pocket cost to the patient — the doctor accepts the Medicare rebate as full payment rather than charging a gap fee on top. Bulk billing rates have been under sustained pressure as the cost of running a practice rose faster than the Medicare rebate itself, pushing more GPs toward charging a gap fee to stay financially viable, which is precisely the dynamic this program is designed to counteract by making full bulk billing more financially sustainable for practices rather than relying on goodwill or patient advocacy alone.
The mechanics of the incentive
To participate, a practice must be registered for MyMedicare — the government's practice-and-patient registration system — and have specifically added the Bulk Billing Practice Incentive Program in the Organisation Register [s1]. Once registered and meeting eligibility criteria, a practice earns the additional 12.5% on every dollar of MBS benefit from eligible bulk-billed services, paid quarterly in arrears starting in the first quarter of 2026 [s1]. The even split between practice and provider is a specific design choice worth noting: it's not simply a payment to the business entity running the clinic, it's structured to also flow additional money directly to the doctor who performed the bulk-billed visit, which more directly targets the individual-level financial disincentive to bulk bill.
Why this is a behavioral incentive, not a rebate increase
This program doesn't raise the base Medicare rebate itself — it adds a conditional bonus on top of it, specifically tied to bulk billing behavior. That's a different policy lever than simply increasing what Medicare pays for a visit regardless of whether it's bulk billed: a straight rebate increase would flow to practices whether or not they bulk bill, while this incentive structure only pays out when a practice actually chooses to charge patients nothing out of pocket. Whether that distinction changes practice behavior more effectively than a general rebate increase would have is a real policy question this program's design implicitly bets on, but the available reporting here doesn't include comparative evidence for that bet.
What this doesn't yet show
The available reporting describes the program's structure, budget, and start date, but doesn't include bulk-billing rate data from after the program's 1 November 2025 launch — meaning it's not yet possible to say from this source whether the financial incentive has actually moved practices toward bulk billing more patients, as opposed to simply subsidizing bulk billing that was already happening at practices that had never stopped.
What to watch next
Whether national bulk-billing rate statistics, once reported for the periods following the program's launch, show a genuine shift among practices that had moved toward gap fees, or whether the $7.9 billion mostly ends up flowing to practices that were bulk billing at high rates already — a distinction that determines whether this program expands patient access or mainly reinforces existing practice behavior.
Sources
- About the Bulk Billing Practice Incentive Program (BBPIP) — Services Australia , November 1, 2025
Young Australians' mental health is recovering. Teenagers are recovering slowest.
Under-25s lost about 5 points on a 100-point wellbeing scale between 2019 and 2021. Adults 19 to 24 have clawed back two-thirds of that loss. Teenagers 15 to 18 have recovered barely a third.
Australia may cut Wegovy from $5,000 a year to $25 a script, for a narrow group
PBAC recommended subsidized listing in November 2025 for adults with obesity and a history of heart attack or stroke. Price negotiations with Novo Nordisk had not concluded.
Australia made vapes pharmacy-only. Usage dipped, and a black market filled in.
Vaping among 18-to-35-year-olds fell from 17.3% to 14.2% in a year, a real decline but a small one against how much vaping had grown before the crackdown.
Indigenous Australians' cardiovascular death rate fell 18%. Suicide got worse.
The national framework tracking First Nations health finds real progress on smoking, education and specific diseases, alongside no movement on infant mortality and worsening suicide.